ABSTRACT
Background: Fatigue is a common side effect in cancer patients undergoing radiation therapy [RT]. Radiation-induced fatigue affects the quality of life, but there is no definitive treatment option, in this study, the weight-loaded forced swim test was performed to assess the effect of coenzyme QIO [CoQIO] on radiation-induced fatigue
Materials and Methods: A total of 60 rats were divided randomly and equally into four groups: No swim, No RT, RT + placebo, or RT + CoQIO. The No swim, No RT, and RT + placebo groups received 1 ml of soybean oil daily for 14 days. The RT + CoQIO group received 100 mg/kg of CoQIO in soybean oil at the same times. Both RT groups were irradiated with 10 Gy on the 14th day of treatment. The swim test with sinkers weighing 10% of body weight was performed 24 h later in all animals except the No swim group
Results: The level of blood urea nitrogen [BUN] was significantly lower in the No swim than the other groups. The BUN level of the No RT group was significantly decreased compared with the RT + placebo group, but it did not differ from the RT + CoQIO group. Swimming times to complete exhaustion were significantly longer in the No RT and RT + CoQIO groups compared to the RT + placebo group [99.4, 105.9, and 75.7 s, respectively] [P<0.001]
Conclusion: Supplementation with CoQIO can prevent the decrease in endurance capacity caused by radiation
Subject(s)
Adult , Animals, Laboratory , Male , Radiotherapy , Fatigue , Rats, Sprague-DawleyABSTRACT
Helicobacter pylori-eliminating effects of FEMY-R7, composed of Laminaria japonica and Oenothera biennis extracts, were investigated in mice and humans. Male C57BL/6 mice were infected with the bacteria by intragastric inoculation (1x10(9) CFU/mouse) 3 times at 2-day intervals, and simultaneously, orally treated twice a day with total 20, 64 or 200 mg/kg/day FEMY-R7 for 2 weeks. In Campylobcter-like organism (CLO)-detection tests on gastric mucosa and feces, FEMY-R7 reduced the urease-positive reactivity in a dose-dependent manner; i.e., the positivity ratios were decreased to 70, 20, and 10% for gastric mocosa and to 80, 50, and 20% for feces. In a clinical sudy, human subjects, confirmed to be infected with Helicobacter pylori, were orally administered twice a day with capsules containing total 100, 320 or 1,000 mg/man/day FEMY-R7 (matching doses for 20, 64 or 200 mg/kg/day, respectively, in mice from a body surface area-based dose translation) for 8 weeks. FEMY-R7 decreased the positivity ratios in feces to 70, 40, and 30%, respectively. In bacterial culture, H. pylori was identified from the CLO-positive stools of mice and humans. The bacterial identification ratios exhibited a good correlation between the matching doses in mice and humans. It is suggested that FEMY-R7 could be a promising functional food without tolerance as an adjunct to reduce the dosage of antibiotics for the treatment of recurrent H. pylori infection.
Subject(s)
Animals , Humans , Male , Mice , Anti-Bacterial Agents , Bacteria , Capsules , Feces , Functional Food , Gastric Mucosa , Helicobacter , Helicobacter pylori , Laminaria , Oenothera biennisABSTRACT
Helicobacter pylori-eliminating effects of FEMY-R7, composed of fucoidan and evening primrose extract, were investigated in mice and humans. Male C57BL/6 mice were infected with the bacteria by intragastric inoculation (1x10(9) CFU/mouse) 3 times at 2-day intervals, and simultaneously, orally treated twice a day with 10 or 100 mg/kg FEMY-R7 for 2 weeks. In Campylobcter-like organism-detection test, FEMY-R7 markedly reduced the urease-positive reactivity. In a clinical sudy, human subjects, confirmed to be infected with Helicobacter pylori, were orally administered twice a day with a capsule containing 150 mg FEMY-R7 for 8 weeks. FEMY-R7 significantly decreased both the Delta over baseline-value in urea breath test and the serum pepsinogens I and II levels. The results indicate that FEMY-R7 not only eliminates H. pylori from gastric mucosa of animals and humans, but also improves gastric function.
Subject(s)
Animals , Humans , Male , Mice , Bacteria , Breath Tests , Gastric Mucosa , Helicobacter , Helicobacter pylori , Oenothera biennis , Pepsinogen A , Pepsinogens , UreaABSTRACT
In 1994, Ajou University Medical Center implemented a hospital information system with a relational database management system(Ingres) and underwent migration using newly improved M technology in 1996. In this paper, a comparison study of database performance between M and RDBMS is presented. Three different types of comparative studies were carried out on the performances of Ingres, Oracle 7.1 (Oracle) and M-Technology(Mumps). Two types of M are adopted to compare with Ingres: Standard M and Open M. The open M was used for DBMS and Standard M was used for writing applications. The system response time was compared by a simple bulk test in a simulated HIS environment. It was found that the performance of Open M was about 100 times faster than that of Ingres. In the live HIS environment, the performance of Open M was found to be 2-8 times faster than Ingres depending on the number of globals involved in the processing of transactions. The performance of Standard M and MSM-SQL was compared with that of Oracle by a simple bulk test in a simulated HIS environment and found that Standard M was more than 100 times faster than Oracle and MSM-SQL was on an average. 1.7 times faster than Oracle. The M was faster than Ingres and Oracle. Despite the cons of RDBMS already discussed, we have found very few pros of RDBMS if M is applied. We have found that conventional RDBMS requires redundant hardware resources which result in slow processing time which HIS manifests in a serious bottleneck during the course of our development and implementation. The performance of M strongly implies that M is most appropriate DB in a HIS environment.